Skip to content

A prospective, single-arm, multi-center phase IV clinical research to evaluate the safety of Jinhua Qinggan Granules in the treatment of influenza

A prospective, single-arm, multi-center phase IV clinical research to evaluate the safety of Jinhua Qinggan Granules in the treatment of influenza

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100005166
Enrollment
Unknown
Registered
2021-08-10
Start date
2021-10-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Interventions

Test group:Jinhua Qinggan granules,1 sachet each time,3 times daily,dissolve in boil water

Sponsors

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Meet the influenza clinical diagnosis standard of "Influenza Diagnosis and Treatment Plan (2020 Edition)"; 2.The age range of patients is over 18 years old (inclusive); 3.The course of disease was within 48 hours; 4.Agree to participate in this study and sign a written informed consent form.

Exclusion criteria

Exclusion criteria: 1. Severe or critically ill patients with influenza; 2. Patients with abnormal liver function; 3. Abnormal blood routine indexes; 4. The patient has test data reflecting abnormal renal function; 5. Pregnant and lactating patients; 6. Combination of serious primary diseases of the heart, brain, lung, liver, kidney and blood system, such as viral hepatitis, hemophilia, mental illness, etc.; 7. According to the judgment of the researcher, there are other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as pregnancy, frequent changes in working environment, unstable living environment, etc., which are likely to cause loss to follow-up; 8. Other investigators judge that there are patients who affect the safety of the drug.

Design outcomes

Primary

MeasureTime frame
Adverse reaction rate;Body temperature normalization rate and hypothermia value;Types of adverse reactions;

Countries

China

Contacts

Public ContactLiu Qingquan

Beijing Traditional Chinese Medicine Hospital Affiliated to Capital Medical University

liu_qingquan_2@126.com+86 13910055687

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026